Advertisement

Advancing Therapeutic Solutions for MCL: Bridging the Gap

June, 06, 2024 | Lymphoma, MCL (Mantle Cell Lymphoma)

KEY TAKEAWAYS

  • The study aimed to investigate real-world outcomes of post-cBTKi treatment in patients with r/r MCL for comprehensive understanding.
  • The results revealed the critical importance of ongoing development of novel therapeutics to address unmet patient needs.

Covalent Bruton’s tyrosine kinase inhibitors (cBTKis) are standard treatment for relapsed/refractory mantle cell lymphoma (r/r MCL), but limited response duration and resistance are observed.

Patrick Squires and the team aimed to assess post-cBTKi clinical and economic outcomes in patients with r/r MCL, addressing existing evidence gaps.

Researchers utilized 2010-2019 U.S. Medicare claims to identify elderly patients (aged ≥66 years) newly diagnosed with MCL. These patients received third-line (3L) treatment and previously demonstrated evidence of cBTKi use. Outcomes evaluated ≥12 months post third-line treatment initiation included treatment patterns, healthcare resource utilization, costs, and overall survival related to both all-cause and mantle cell lymphoma-specific factors.

About 230 elderly patients with r/r MCL who underwent 3L treatment revealed that all had previously been exposed to cBTKis in earlier therapy regimens. Their mean age was 75.0, with 21.7% aged over 80 years, and the majority were male (67.4%) and White (93.9%).

Among the common 3L treatments administered, chemotherapy (26.1%), lenalidomide (18.7%), and bortezomib (18.3%) were prominent. A quarter of patients (25.7%) received a cBTKi, predominantly ibrutinib (17.8%) and acalabrutinib (7.8%).

The overall survival post-3L treatment initiation was notably low, with a median of 9.4 months and a 1-year survival rate of 43.7%. Patients exhibited elevated healthcare resource utilization, with 73.6% experiencing hospitalization, and incurred substantial costs, averaging $145,726 within the 12 months following 3L initiation.

The study concluded that within this patient subpopulation, a significant unmet need persists, underscoring the critical importance of continued advancement in the development of novel therapeutics.

This study was supported by Bristol Myers Squibb.

Source: https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(24)00226-X/abstract#articleInformation

Squires P, Puckett J, Ryland KE, et al. (2024). “Real-world Treatment Patterns, Survival, and Economic Burden among Elderly MCL Patients Previously Treated with cBTKis.” DOI: https://doi.org/10.1016/j.clml.2024.05.023

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy